BRIEF-Endo Pharmaceuticals presents new mid-stage data evaluating safety and effectiveness of Xiaflex

Fri Sep 30, 2016 7:45am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Sept 30 (Reuters) - Endo International Plc

* Endo Pharmaceuticals presents new phase 2 data evaluating the safety and effectiveness of Xiaflex(collagenase clostridium histolyticum) for dupuytren's disease nodules

* Safety profile of those treated with CCH was generally well tolerated

* Study participants treated with 1 injection of Xiaflex showed statistically significant decrease in size, hardness of dupuytren's disease nodules

* One adverse event was reported as severe (injection site pain with CCH 0.60 mg)

* No patients were discontinued from study because of an adverse event. Source text for Eikon: Further company coverage: